Successfully Integrating Radium Ra 223 Dichloride Injection Into a Urology Practice.
作者信息
McMahon Gregory C, Brown Gordon A
机构信息
Department of Urology, Rowan University Stratford NJ.
Center for Advanced Therapeutics, Delaware Valley Urology Voorhees, NJ.
出版信息
Rev Urol. 2017;19(4):248-251. doi: 10.3909/riu0782.
Abstract
摘要
相似文献
1
Successfully Integrating Radium Ra 223 Dichloride Injection Into a Urology Practice.成功将二氯化镭Ra 223注射液纳入泌尿外科临床实践。
Rev Urol. 2017;19(4):248-251. doi: 10.3909/riu0782.
2
Radium Ra 223 dichloride in castration-resistant prostate cancer.二氯化镭 Ra 223 用于去势抵抗性前列腺癌
Drugs Today (Barc). 2013 Aug;49(8):483-90. doi: 10.1358/dot.2013.49.8.1968670.
3
Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice.镭-二氯化物在去势抵抗性转移性前列腺癌中的应用：改善临床实践中的结局并识别生存预测因素。
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2264-2273. doi: 10.1007/s00259-018-4083-3. Epub 2018 Jul 11.
4
A unique drug distribution process for radium Ra 223 dichloride injection and its implication for product quality, patient privacy, and delineation of professional responsibilities.二氯化镭Ra 223注射液独特的药物配送流程及其对产品质量、患者隐私和专业职责界定的影响。
Ann Pharmacother. 2014 Nov;48(11):1512-4. doi: 10.1177/1060028014545644.
5
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.二氯化镭-223治疗转移性去势抵抗性前列腺癌：泌尿外科医生的观点
Urology. 2015 Apr;85(4):717-24. doi: 10.1016/j.urology.2014.11.031. Epub 2015 Feb 11.
6
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.镭 223 二氯化物注射液：美国食品药品监督管理局药物批准摘要。
Clin Cancer Res. 2014 Jan 1;20(1):9-14. doi: 10.1158/1078-0432.CCR-13-2665. Epub 2013 Nov 4.
7
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.发射α粒子的二氯化镭（²²³Ra）靶向放射性核素治疗中骨转移灶的剂量测定
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):21-33. doi: 10.1007/s00259-015-3150-2. Epub 2015 Aug 13.
8
Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.二氯化镭-223：一种用于有症状骨转移的去势抵抗性前列腺癌患者的新型治疗选择。
Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Epub 2015 Jan 8.
9
Impact of pre-treatment variables on the completion of radium-dichloride therapy in mCRPC patients with bone metastases.预处理变量对伴有骨转移的mCRPC患者二氯化镭治疗完成情况的影响。
Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:153-163.
10
Compartmental Model for Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer.放射性氯化镭在去势抵抗性前列腺癌骨转移患者中的房室模型。
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):884-892. doi: 10.1016/j.ijrobp.2019.07.022. Epub 2019 Jul 23.
引用本文的文献
1
Factors Influencing Outcome Post-Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges.影响去势抵抗性前列腺癌患者接受二氯化镭-223治疗后预后的因素：一些现实挑战的综述
World J Nucl Med. 2022 Sep 2;21(4):283-289. doi: 10.1055/s-0042-1750015. eCollection 2022 Dec.
2
Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.镭-223治疗转移性前列腺癌的不良事件：对反映全球使用情况的FDA数据进行的不成比例分析
Clin Genitourin Cancer. 2020 Jun;18(3):192-200.e2. doi: 10.1016/j.clgc.2019.11.017. Epub 2019 Dec 5.
3
Evaluation of N-Succinimidyl S-Acetylthioacetate Ligand for Radiolabeling of Humanized Antibodies with Rhenium.用铼标记人源化抗体的 N-琥珀酰亚胺基 S-乙酰硫代乙酸配体的评价。
Cancer Biother Radiopharm. 2018 Oct;33(8):349-355. doi: 10.1089/cbr.2018.2480. Epub 2018 Jul 16.
本文引用的文献
1
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
2
Radium Ra 223 Dichloride Therapy in the Private Practice Environment.私人执业环境下的二氯化镭 Ra 223 疗法
Rev Urol. 2016;18(2):106-9. doi: 10.3909/riu0720.
3
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.患有前列腺癌骨转移的医疗保险参保者中骨相关事件的临床和经济影响。
Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.
4
Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.雄激素受体对前列腺癌肿瘤细胞可塑性的调控
Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1.
5
Multidisciplinary management of Prostate Cancer: how and why.前列腺癌的多学科管理：方式与原因
Am J Clin Exp Urol. 2013 Dec 25;1(1):12-7. eCollection 2013.
6
Clinical phenotypes of castration-resistant prostate cancer.去势抵抗性前列腺癌的临床表型
Clin Adv Hematol Oncol. 2013 Nov;11(11):707-18.
7
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.转移性去势抵抗性前列腺癌的最佳管理：欧洲专家共识小组的要点。
Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.
8
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.镭 223 二氯化物注射液：美国食品药品监督管理局药物批准摘要。
Clin Cancer Res. 2014 Jan 1;20(1):9-14. doi: 10.1158/1078-0432.CCR-13-2665. Epub 2013 Nov 4.
9
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.使用患者报告结局测量评估转移性前列腺癌男性的疼痛和镇痛药物使用的流行情况。
J Oncol Pract. 2013 Sep;9(5):223-9. doi: 10.1200/JOP.2013.000876. Epub 2013 Jun 25.
10
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
Zotero 插件